<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01616277</url>
  </required_header>
  <id_info>
    <org_study_id>B5161001</org_study_id>
    <nct_id>NCT01616277</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study To Evaluate The Safety And Tolerability Of PF-06252616 In Healthy Subjects</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-06252616 In Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if the study drug, PF-06252616 is safe and well
      tolerated when given to adult healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment related Adverse Events.</measure>
    <time_frame>Day 197</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of treatment related Adverse Events.</measure>
    <time_frame>Day 197</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of abnormal lab findings.</measure>
    <time_frame>Day 197</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Magnitude of abnormal lab findings.</measure>
    <time_frame>Day 197</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Abnormal and clinically relevant changes in Blood Pressure.</measure>
    <time_frame>Day 197</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Abnormal and clinically relevant changes in Pulse Rate.</measure>
    <time_frame>Day 197</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Abnormal and clinically relevant changes in Respiratory Rate.</measure>
    <time_frame>Day 197</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Abnormal and clinically relevant changes in temperature.</measure>
    <time_frame>Day 197</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Abnormal and clinically relevant changes in ECG parameters.</measure>
    <time_frame>Day 197</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PF-06252616 concentration in serum as measured by a validated PK assay for Cmax (maximum concentration)</measure>
    <time_frame>Through Day 197 post dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic activity as measured by serum concentrations of GDF-8 (myostatin) as measured by a GDF-8 assay</measure>
    <time_frame>Through Day 197 post dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of development of anti-drug antibody (ADA) as measured by an ADA assay</measure>
    <time_frame>Through Day 197 post dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacologic activity as measured by the percent change in lean body mass as measured by DXA</measure>
    <time_frame>Through Day 113 post dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PF-06252616 concentration in serum as measured by a validated PK assay for Tmax (time to reach maximum concentration)</measure>
    <time_frame>Through Day 197 post dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PF-06252616 concentration in serum as measured by a validated PK assay for AUCinf (area under the curve serum concentration-time profile from time zero to infinity</measure>
    <time_frame>Through Day 197 post dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PF-06252616 concentration in serum as measured by a validated PK assay for AUClast (area under the curve serum concentration from time zero to the time of the last quantifiable concentration)</measure>
    <time_frame>Through Day 197 post dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PF-06252616 concentration in serum as measured by a validated PK assay for t1/2 (half-life time for the serum concentration to decrease by half).</measure>
    <time_frame>Through Day 197 post dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PF-06252616 concentration in serum as measured by a validated PK assay for AUCÏ„ (area under the curve serum concentration by dose interval)</measure>
    <time_frame>Through Day 197 post dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PF-06252616 concentration in serum as measured by a validated PK assay for MRT (mean residence time)</measure>
    <time_frame>Through Day 197 post dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PF-06252616 concentration in serum as measured by a validated PK assay for CL (rate of clearance from serum)</measure>
    <time_frame>Through Day 197 post dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PF-06252616 concentration in serum as measured by a validated PK assay for CLss (rate of steady state clearance from serum in the repeat dose cohort)</measure>
    <time_frame>Through Day 197 post dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PF-06252616 concentration in serum as measured by a validated PK assay for Vz /F(volume of distribution is the theoretical volume which the total amount of drug would need to be uniformly distributed to produce the desired concentration of a drug.)</measure>
    <time_frame>Through Day 197 post dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PF-06252616 concentration in serum as measured by a validated PK assay for Vss(volume of distribution is the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired concentration of a drug.</measure>
    <time_frame>Through Day 197 post dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steady state volume of distribution is the apparent volume of distribution at steady-state.)</measure>
    <time_frame>Through Day 197 post dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PF-06252616 concentration in serum as measured by a validated PK assay for RAC (accumulation ratio for AUC)</measure>
    <time_frame>Through Day 197 post dosing</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">86</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Repeat dose of PF-06252616, IV infusion, single dose - 10.0 miligram per kilogram</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>7</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-06252616</intervention_name>
    <description>1.0 milligram per kilogram of PF-06252616, IV infusion, single dose</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for PF-06252616, IV infusion, single dose</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-06252616</intervention_name>
    <description>3.0 milligram per kilogram of PF-06252616, IV infusion, single dose</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for PF-06252616, IV infusion, single dose</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-06252161</intervention_name>
    <description>10.0 milligram per kilogram of PF-06252616, IV infusion, single dose</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for PF-06252616, IV infusion, single dose</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-06252616</intervention_name>
    <description>3.0 milligram per kilogram of PF-06252616, Subcutaneous injection, single dose</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for PF-06252616, Subcutaneous injection, single dose</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-06252616</intervention_name>
    <description>10.0 miligram per kilogram of PF-06252616, IV infusion, repeat dose</description>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for PF-06252616, IV infusion, repeat dose</description>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-06252616</intervention_name>
    <description>20.0 milligram per kilogram of PF-06252616, IV infusion, single dose</description>
    <arm_group_label>6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for PF-06252616, IV infusion, single dose</description>
    <arm_group_label>6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-06252616</intervention_name>
    <description>40.0 milligram per kilogram of PF-06252616, IV infusion, single dose</description>
    <arm_group_label>7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for PF-06252616, IV infusion, single dose</description>
    <arm_group_label>7</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Single Dose Cohorts-Healthy male and/or female non-child bearing subjects between the
             ages of 18 and 55 years, inclusive.

          -  Repeat Dose Cohort-Healthy male and/or female non-child bearing subjects between the
             ages of 18 and less than 65 years, inclusive.

        Exclusion Criteria:

          -  Presence or history of muscle disease (eg, polymyositis or rhabdomyolysis).

          -  Weight loss or gain of &gt;5% within 30 days of Screening, as reported by subject.

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic,
             immunologic, metabolic urologic, dermatologic, renal, allergic disease (including drug
             allergies, but excluding untreated, asymptomatic, seasonal allergies at time of
             dosing) and any other major disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B5161001&amp;StudyName=A%20Phase%201%20Study%20To%20Evaluate%20The%20Safety%20And%20Tolerability%20Of%20PF-06252616%20In%20Healthy%20Subjects</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 25, 2012</study_first_submitted>
  <study_first_submitted_qc>June 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2012</study_first_posted>
  <last_update_submitted>September 23, 2014</last_update_submitted>
  <last_update_submitted_qc>September 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

